Enrico Capochiani

1.1k total citations
26 papers, 699 citations indexed

About

Enrico Capochiani is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Enrico Capochiani has authored 26 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 12 papers in Pathology and Forensic Medicine and 9 papers in Oncology. Recurrent topics in Enrico Capochiani's work include Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Viral-associated cancers and disorders (5 papers). Enrico Capochiani is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Viral-associated cancers and disorders (5 papers). Enrico Capochiani collaborates with scholars based in Italy, Switzerland and Germany. Enrico Capochiani's co-authors include F Caracciolo, G Pasero, Cesare Mazzaro, Monica Monti, Alessandro Mazzoni, Francesco Greco, Clodoveo Ferri, Anna Linda Zignego, G. Longombardo and L La Civita and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Annals of Oncology.

In The Last Decade

Enrico Capochiani

25 papers receiving 671 citations

Peers

Countries citing papers authored by Enrico Capochiani

Since Specialization

Citations

This map shows the geographic impact of Enrico Capochiani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enrico Capochiani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enrico Capochiani more than expected).

Fields of papers citing papers by Enrico Capochiani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Enrico Capochiani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enrico Capochiani. The network helps show where Enrico Capochiani may publish in the future.

Co-authorship network of co-authors of Enrico Capochiani

This figure shows the co-authorship network connecting the top 25 collaborators of Enrico Capochiani. A scholar is included among the top collaborators of Enrico Capochiani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enrico Capochiani. Enrico Capochiani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prospective study on the impact of BEAM versus FEAM conditioning on occurrence of neutropenic enterocolitis and on transplant outcome in lymphoma patients 2024 ·Frontiers in Oncology ·E. Benedetti, (unknown), Giulia Pucci, Riccardo Morganti, Emilia Bramanti, Federica Cavallo, Enrico Capochiani, Maurizio De Maria, (unknown), (unknown), Sara Galimberti	1
2	Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease 2023 ·Journal of Clinical Medicine ·E. Benedetti, Claudia Baratè, (unknown), Emilia Bramanti, Riccardo Morganti, (unknown), Giulia Cervetti, Enrico Capochiani, (unknown), (unknown), (unknown), Benedetto Bruno, Sara Galimberti	1
3	Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany 2023 ·Clinical and Experimental Medicine ·Claudia Baratè, Alessandro Sanna, E. Benedetti, Monica Bocchia, Enrico Capochiani, Romano Danesi, Sabrina Moretti, (unknown), Simone Santini, Sara Galimberti, Alessandro Gozzetti	1
4	Unusual presentation of extranodal diffuse large B-cell lymphoma in a solid-organ recipient during long-term immunosuppressive treatment 2021 ·Tumori Journal ·(unknown), Emanuela Sant’Antonio, (unknown), (unknown), (unknown), Elena Banti, (unknown), (unknown), (unknown), Federico Simonetti, Enrico Capochiani	0
5	Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol 2020 ·Frontiers in Medicine ·Enrico Capochiani, Bruno Frediani, Giorgio Iervasi, Aldo Paolicchi, Spartaco Sani, (unknown), Annarosa Cuccaro, Federico Franchi, Federico Simonetti, Davide Carrara, (unknown), (unknown), (unknown), Sabino Scolletta, Serafina Valente, Edoardo Conticini, Alessandro Gozzetti, Monica Bocchia	42
6	Chronic Myeloid Leukemia Patient’s Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial 2019 ·Frontiers in Psychology ·Lidia Borghi, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Enrico Capochiani, Antonio Cuneo, Franca Falzetti, Alessandra Iurlo, Francesca Lunghi, Claudia Minotto, Ester Orlandi, Giovanna Rege‐Cambrin, Simona Sica, (unknown), (unknown), Elena Vegni	5
7	Recovering from chronic myeloid leukemia: the patients’ perspective seen through the lens of narrative medicine 2017 ·Quality of Life Research ·Guendalina Graffigna, (unknown), Massimo Breccia, Enrico Capochiani, (unknown), Sara Galimberti, (unknown), Federico Simonetti, Michele Pizzuti, Silvana Capalbo, Franca Falzetti, Patrizio Mazza, Nicola Di Renzo, Lucia Mastrullo, Davide Rapezzi, Ester Orlandi, Tamara Intermesoli, Alessandra Iurlo, (unknown), (unknown)	20
8	Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab) 2016 ·Annals of Oncology ·Mathias Rummel, (unknown), Franco Aversa, Wolfram Brugger, Enrico Capochiani, (unknown), Francesca Re, Peter C. Trask, Stuart Osborne, Rodney B.W. Smith, Andrew Grigg	100
9	Prefmab: Final Analysis Of Patient Satisfaction With Subcutaneous Versus Intravenous Rituximab In Previously Untreated Cd20+ Diffuse Large B-Cell Lymphoma Or Follicular Lymphoma 2015 ·Value in Health ·Mathias Rummel, (unknown), (unknown), Enrico Capochiani, (unknown), Rodney B.W. Smith, Stuart Osborne, Andrew Grigg	2
10	Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute 2014 ·Value in Health ·Simon Rule, Javier Briones, Rodney B.W. Smith, (unknown), (unknown), Stuart Osborne, Enrico Capochiani, Mathias Rummel	13
11	Heart Involvement in T Cell Lymphoma Through Hypereosinophilic Syndrome: A Common Complication of a Rare Condition 2005 ·Journal of Cardiovascular Magnetic Resonance ·(unknown), Massimo Lombardi, Enrico Capochiani, U Simi, Maria Teresa Savoia, (unknown), A. M. DiGiorgio, (unknown), (unknown), Michele Galli	1
12	Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma 2000 ·Movement Disorders ·Angelo Nuti, Roberto Ceravolo, (unknown), Gianna Gambaccini, Ubaldo Bonuccelli, Enrico Capochiani	24
13	Renal carcinoma in two patients with poor prognosis NHL treated with high-dose chemotherapy and peripheral stem cell autotransplantation 1999 ·Haematologica ·F Caracciolo, Federico Papineschi, E. Benedetti, Enrico Capochiani, Nadia Cecconi, (unknown), A Azzarà, (unknown), (unknown), (unknown), (unknown), Mario Petrini	1
14	Interferon-α in the idiopathic hypereosinophilic syndrome: consideration of five cases 1998 ·Annals of Hematology ·(unknown), Enrico Capochiani, Mario Petrini	53
15	A new effective treatment for indolent lymphoma: a pilot study with fludarabine, idarubicin and prednisone combination (FLIDA) 1997 ·Hematological Oncology ·F Caracciolo, Enrico Capochiani, Federico Papineschi, Mario Petrini	6
16	Consolidation Therapy with Idarubicin, Cisplatin and Prednisone (CIP) After P-VABEC Regimen in the Treatment of Intermediate and High Grade Non-Hodgkin's Lymphoma of the Elderly 1997 ·Leukemia & lymphoma ·F Caracciolo, Enrico Capochiani, Federico Papineschi, Mario Petrini	4
17	Hepatitis C virus infection in patients with non‐Hodgkin's lymphoma 1994 ·British Journal of Haematology ·Clodoveo Ferri, F Caracciolo, Anna Linda Zignego, L La Civita, Monica Monti, G. Longombardo, Francesco Lombardini, Francesco Greco, Enrico Capochiani, Alessandro Mazzoni, Cesare Mazzaro, G Pasero	357
18	Alternating chemotherapy regimen (P‐VABEC) for intermediate and high‐grade non‐Hodgkin's lymphoma of the middle aged and elderly 1994 ·Hematological Oncology ·F Caracciolo, Massimiliano Petrini, Enrico Capochiani, Federico Papineschi, Giovanni Carulli, Bruno Grassi	9
19	Recombinant α2a interferon and polycythemia vera: Clinical results and biological evaluation by means of Fourier‐transform infrared microspectroscopy 1994 ·European Journal Of Haematology ·Federico Papineschi, Alessandro Bucalossi, Enrico Capochiani, E. Benedetti, Emilia Bramanti, Giuseppe Dastoli, (unknown), (unknown)	14
20	Third Generation Chemotherapy with P-VABEC for Aggressive Non-Hodgkin's Lymphomas of the Elderly 1993 ·Leukemia & lymphoma ·F Caracciolo, Mario Petrini, Enrico Capochiani, Federico Papineschi, Bruno Grassi	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact